Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Company Profile

Stronger Sell Today AKBA ranks #6045 as SELL CANDIDATE #6045 Weaker Sell

AKBA stock forecast Akebia Therapeutics

AKBA stock forecast

Akebia Therapeutics

245 First Street

Cambridge, MA 02142


Industry: Biotechnology

Sector: Healthcare


Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is AKB-6899, a small molecule HIF-PH inhibitor to treat oncology and ophthalmology. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank